← Back to Search

Menin Inhibitor

Arm 1 for Leukemia

Phase 2

Waitlist Available

Led By Ghayas Issa, MD

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

ECOG performance status of ≤ 2

Relapsed or refractory acute leukemia, of either myeloid, lymphoid or mixed lineages, with specific genetic alterations associated with upregulation of HOX

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion; an average of 1 year.

Awards & highlights

Study Summary

This trial is testing if a drug called revumenib can help to control certain types of leukemia that are related to increased expression of HOX genes.

Who is the study for?

This trial is for individuals with leukemia that's linked to high activity of HOX genes. Specific eligibility details are not provided, but typically participants would need a confirmed diagnosis and may have to meet certain health requirements.Check my eligibility

What is being tested?

The study is testing the effectiveness of Revumenib, a Menin inhibitor, in managing leukemia where there's an upregulation of HOX genes. It aims to determine if this drug can control the disease.See study design

What are the potential side effects?

Potential side effects for Revumenib aren't listed here, but common ones for cancer drugs include nausea, fatigue, risk of infection, and blood count changes. The exact side effects will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can take care of myself and am up and about more than half of my waking hours.

Select...

My leukemia has returned or is not responding to treatment and has specific genetic changes.

Select...

My kidneys work well, with a filtration rate of at least 60 mL/min.

Select...

I agree to use birth control during and for 3 months after the study.

Select...

I am 12 years or older and weigh at least 40kg.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion; an average of 1 year.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion; an average of 1 year.

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion; an average of 1 year. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Safety and adverse events (AEs)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Arm 1Experimental Treatment1 Intervention

Participants found to be eligible to take part in this study, will take revumenib 2 times a day (each dose about 12 hours apart), every day of each 28-day study cycle.

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,966 Previous Clinical Trials

1,804,766 Total Patients Enrolled

451 Trials studying Leukemia

31,452 Patients Enrolled for Leukemia

Syndax PharmaceuticalsIndustry Sponsor

48 Previous Clinical Trials

2,759 Total Patients Enrolled

8 Trials studying Leukemia

616 Patients Enrolled for Leukemia

Ghayas Issa, MDPrincipal InvestigatorM.D. Anderson Cancer Center

2 Previous Clinical Trials

51 Total Patients Enrolled

1 Trials studying Leukemia

43 Patients Enrolled for Leukemia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent does Arm 1 pose a risk to individuals' well-being?

"Based on the nature of this Phase 2 trial, Arm 1 received a safety rating of 2 from our team at Power. While there is some evidence supporting its safety, no data has been found yet to support its effectiveness."

Answered by AI

Are there any available positions for patients to participate in this clinical trial?

"Based on the information from clinicaltrials.gov, this trial is currently not seeking participants. The initial posting date for this study was July 31st, 2024, and it was last edited on January 18th, 2024. However, there are currently a total of 1386 other trials actively enrolling participants at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

2024. "A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06229912.

All > Leukemia